Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 7Lymphoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Recurrence 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Solid Tumors 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Ketoconazole × Clear all
NCT01765556 2016-11-02

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 1 Withdrawn
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡